UK Markets closed
  • NIKKEI 225

    28,147.51
    -461.08 (-1.61%)
     
  • HANG SENG

    28,231.04
    +217.23 (+0.78%)
     
  • CRUDE OIL

    65.82
    +0.54 (+0.83%)
     
  • GOLD FUTURES

    1,819.90
    -16.20 (-0.88%)
     
  • DOW

    33,587.66
    -681.50 (-1.99%)
     
  • BTC-GBP

    34,794.02
    -3,994.06 (-10.30%)
     
  • CMC Crypto 200

    1,468.19
    -95.64 (-6.12%)
     
  • Nasdaq

    13,031.68
    -357.75 (-2.67%)
     
  • ^FTAS

    3,986.82
    +23.84 (+0.60%)
     

World Acne Market Spotlight Report 2021: GlaxoSmithKline has the Highest Number of Completed Clinical Trials for Acne with 35 Trials

Research and Markets
·3-min read

Dublin, April 12, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Acne" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2019, there were approximately 612.5 million prevalent cases of acne worldwide, and forecasts that number to increase to 658.6 million prevalent cases by 2028.

Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.

The majority of industry-sponsored drugs in active clinical development for acne are in Phase II, with just a single product in the NDA/BLA stage.

Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.

The only high-impact upcoming event for drugs in the acne space is an expected PDUFA date for Twyneo. The overall likelihood of approval of a Phase I dermatology-general asset is 20.2%, and the average probability a drug advances from Phase III is 68%. Drugs, on average, take 8.8 years from Phase I to approval in the dermatology-general space, as well as in the overall dermatology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for acne have been in the late phases of development, with 52% of trials in Phase III-IV, and 48% in Phase I-II.

The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.

GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for acne, followed by AbbVie.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Topical therapy

  • Systemic therapy

  • Physical treatments

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • VB 1953 for Acne (June 16, 2020)

  • DMT310 for Acne (June 10, 2020)

  • FCD105 for Acne (June 2, 2020)

  • Twyneo for Acne (December 30, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Cassiopea's Winlevi Brings New Drug Class To Acne Market

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • GSK Inks Dermatology Pact With Eligo

  • L'Oreal's Microbiome Explorations Lead To Micreos Deal For Next-Gen Antibacterial

  • Paratek, Almirall Partner To Bring Acne Medicine To China

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status

  • Sponsors by phase

  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/8ld71

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900